These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 16857431)
1. Topoisomerase II and the etiology of chromosomal translocations. Felix CA; Kolaris CP; Osheroff N DNA Repair (Amst); 2006 Sep; 5(9-10):1093-108. PubMed ID: 16857431 [TBL] [Abstract][Full Text] [Related]
2. Leukemias related to treatment with DNA topoisomerase II inhibitors. Felix CA Med Pediatr Oncol; 2001 May; 36(5):525-35. PubMed ID: 11340607 [TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Domer PH; Head DR; Renganathan N; Raimondi SC; Yang E; Atlas M Leukemia; 1995 Aug; 9(8):1305-12. PubMed ID: 7643617 [TBL] [Abstract][Full Text] [Related]
5. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Broeker PL; Super HG; Thirman MJ; Pomykala H; Yonebayashi Y; Tanabe S; Zeleznik-Le N; Rowley JD Blood; 1996 Mar; 87(5):1912-22. PubMed ID: 8634439 [TBL] [Abstract][Full Text] [Related]
6. Secondary leukemias induced by topoisomerase-targeted drugs. Felix CA Biochim Biophys Acta; 1998 Oct; 1400(1-3):233-55. PubMed ID: 9748598 [TBL] [Abstract][Full Text] [Related]
7. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Lovett BD; Lo Nigro L; Rappaport EF; Blair IA; Osheroff N; Zheng N; Megonigal MD; Williams WR; Nowell PC; Felix CA Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9802-7. PubMed ID: 11493704 [TBL] [Abstract][Full Text] [Related]
8. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Felix CA; Hosler MR; Winick NJ; Masterson M; Wilson AE; Lange BJ Blood; 1995 Jun; 85(11):3250-6. PubMed ID: 7756657 [TBL] [Abstract][Full Text] [Related]
9. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Strick R; Strissel PL; Borgers S; Smith SL; Rowley JD Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4790-5. PubMed ID: 10758153 [TBL] [Abstract][Full Text] [Related]
10. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Andersen MK; Christiansen DH; Jensen BA; Ernst P; Hauge G; Pedersen-Bjergaard J Br J Haematol; 2001 Sep; 114(3):539-43. PubMed ID: 11552977 [TBL] [Abstract][Full Text] [Related]
11. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Whitmarsh RJ; Saginario C; Zhuo Y; Hilgenfeld E; Rappaport EF; Megonigal MD; Carroll M; Liu M; Osheroff N; Cheung NK; Slater DJ; Ried T; Knutsen T; Blair IA; Felix CA Oncogene; 2003 Nov; 22(52):8448-59. PubMed ID: 14627986 [TBL] [Abstract][Full Text] [Related]
12. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Aplan PD; Chervinsky DS; Stanulla M; Burhans WC Blood; 1996 Apr; 87(7):2649-58. PubMed ID: 8639880 [TBL] [Abstract][Full Text] [Related]
13. Chromatin structural elements and chromosomal translocations in leukemia. Zhang Y; Rowley JD DNA Repair (Amst); 2006 Sep; 5(9-10):1282-97. PubMed ID: 16893685 [TBL] [Abstract][Full Text] [Related]
14. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Strissel PL; Strick R; Rowley JD; Zeleznik-Le NJ Blood; 1998 Nov; 92(10):3793-803. PubMed ID: 9808573 [TBL] [Abstract][Full Text] [Related]
15. Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. Ahuja HG; Felix CA; Aplan PD Genes Chromosomes Cancer; 2000 Oct; 29(2):96-105. PubMed ID: 10959088 [TBL] [Abstract][Full Text] [Related]
16. [Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs]. Dassonneville L; Bailly C Bull Cancer; 1998 Mar; 85(3):254-61. PubMed ID: 9752316 [TBL] [Abstract][Full Text] [Related]
18. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions. Sung PA; Libura J; Richardson C DNA Repair (Amst); 2006 Sep; 5(9-10):1109-18. PubMed ID: 16809075 [TBL] [Abstract][Full Text] [Related]
19. Bioflavonoids promote stable translocations between MLL-AF9 breakpoint cluster regions independent of normal chromosomal context: Model system to screen environmental risks. Bariar B; Vestal CG; Deem B; Goodenow D; Ughetta M; Engledove RW; Sahyouni M; Richardson C Environ Mol Mutagen; 2019 Mar; 60(2):154-167. PubMed ID: 30387535 [TBL] [Abstract][Full Text] [Related]
20. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Felix CA; Lange BJ; Hosler MR; Fertala J; Bjornsti MA Cancer Res; 1995 Oct; 55(19):4287-92. PubMed ID: 7671237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]